Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.
about
Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapyThe efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus.Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes.Clinical application of transcriptional activators of bile salt transporters.Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.Concept on the pathogenesis and treatment of primary biliary cirrhosisThe PXR is a drug target for chronic inflammatory liver disease.Review article: pruritus in cholestatic and other liver diseases.Risk factors for idiosyncratic drug-induced liver injury.Management of pruritus in chronic liver disease.Causality assessment in drug-induced hepatotoxicity.FXR and PXR: potential therapeutic targets in cholestasis.Proposed therapies in primary biliary cholangitis.Clinical features and management of primary biliary cirrhosis.Nuclear receptors as therapeutic targets in cholestatic liver diseases.Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.Pathogenesis and management of pruritus in cholestatic liver disease.Current pharmacotherapy for cholestatic liver disease.Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.Application of urine proteomics for biomarker discovery in drug-induced liver injury.Novel therapeutic targets in primary biliary cirrhosis.A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis.Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.Novel strategies and therapeutic options for the management of primary biliary cholangitis.Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus.Pathogenesis of cholestatic itch: old questions, new answers, and future opportunities.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids.Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.Searching for Bacterial Biofilm in Recurrent Cholangitis in Primary Sclerosing Cholangitis: A Case Presentation and Introduction of an Unexplored Disease Mechanism.Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.Primary biliary cirrhosisIleal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASHDrug-induced cholestasis
P2860
Q25255438-9DA7CA72-01FF-48B6-AE06-B4B29FD129B3Q26853649-EEE7C7DB-85B5-45AD-AD86-DDFA4A66BCA2Q33280833-3E7DCF1C-E774-4864-9738-631BE00E1C7FQ33296074-7CB7CCCD-3A39-4AB9-BD57-E357F3B5BBF5Q33709930-28A7639F-9B25-4933-8E19-0610E37AAD7BQ33721771-1331D45E-9AA4-4FBB-AB32-3F493560D8C3Q33866454-38F7CFB9-EF03-45A2-8A93-4206EE5D9E6AQ34118368-322EB6D6-C8A6-4A24-A717-B87FCC29F1BDQ35091959-AF03731B-0CAF-408B-AA07-150F76269CEEQ35168108-C05F2621-257E-4AE8-8231-79854F13CDD1Q35226847-9DA1DDBB-A2AA-4F9B-A9EA-FBF758B3EBC5Q35842573-AC31A701-3F4B-4104-8209-F80E13887C34Q36572561-2D6ADCA4-7EEE-4A02-B24B-F86BE54C4517Q37072380-FD5AEB4A-A58B-4A22-80F5-878539A732DEQ37182934-CF00F1E6-71FD-48D1-9548-1F0FE08C7B08Q37230857-0438F8DC-FC6F-40B0-AF81-EAD9635B1F88Q37351504-4EF260BA-9F2F-4F6D-AA01-58F269D5A681Q37613267-11297841-A0F4-4BC6-9302-20FB638E2108Q37993126-A1AD372C-DDA2-419F-A415-8BA2F15F4A19Q38055205-39B7762B-D8EB-48C8-B3EA-66E8F83E5988Q38175055-35467CC2-D29F-442A-BA17-D14854E1AFDFQ38255178-323CB32F-C5BA-41B2-AFE9-77D9B2DF1151Q38342107-E3C13C1D-771B-4C57-A270-4B2025C62953Q38637490-CA5D5B3A-3B80-4AC0-884F-BDBD3FD2AD5FQ39293482-FF72FDFB-A099-459F-A9DE-F9DF6E0FD6ADQ42375647-F8036261-7B99-4415-92C8-12173D2D6CFDQ43230366-F160A696-64C3-4F77-88DE-E3182EA3BD58Q51598664-4C5FB349-8C40-4C94-800B-0EDCED3150F6Q52624982-F5A061E1-FB6A-486F-8A85-ECBAD2348063Q54375811-59E025B3-E5FA-4608-8721-69A6FA1BD2F9Q54980590-C7FB7AE2-8254-48ED-84E5-D7B1357DC8C2Q54982596-5BE041F1-F028-4112-8053-2306E91195C2Q55192048-4A2B3033-8B64-4869-91CF-41EEC673D2ACQ56428273-950B8EB4-7365-458D-9206-D05F1BAE4809Q57099106-29905977-0DA2-405C-870A-5E1842594109Q57126212-B410C3EF-F11F-4B82-89BB-4233B4F72C71
P2860
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Hepatitis and liver dysfunctio ...... in primary biliary cirrhosis.
@ast
Hepatitis and liver dysfunctio ...... in primary biliary cirrhosis.
@en
type
label
Hepatitis and liver dysfunctio ...... in primary biliary cirrhosis.
@ast
Hepatitis and liver dysfunctio ...... in primary biliary cirrhosis.
@en
prefLabel
Hepatitis and liver dysfunctio ...... in primary biliary cirrhosis.
@ast
Hepatitis and liver dysfunctio ...... in primary biliary cirrhosis.
@en
P2860
P356
P1433
P1476
Hepatitis and liver dysfunctio ...... s in primary biliary cirrhosis
@en
P2093
D E J Jones
M I Prince
P2860
P304
P356
10.1136/GUT.50.3.436
P407
P577
2002-03-01T00:00:00Z